This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Franco et al.1 investigated the utility of standardized methods for assessing the adverse effects (AEs) of antiepileptic drugs (AEDs). That is an important matter because it has been shown that quality of life in epilepsy is strongly correlated with AE burden from AEDs.2 The authors were inspired in a previous study from Gilliam et al.3 showing the effectiveness of systematic screening of AEs of AEDs using a self-administered standardized instrument—the Adverse Events Profile (AEP)—versus conventional clinical management. In contrast to the pioneering study of Gilliam et al., Franco and colleagues did not find a significant difference in improvement in AEP scores between patients treated by physicians who were aware of the score before the visit and those treated by physicians who were unaware of it. It is worth mentioning that—although modest—they identify an improvement in AEP scores and quality of life in both groups over time, despite a small increase in AED load by the end of the study. This finding may be explained by a rise in awareness on reporting and screening for AEs by patients and physicians, respectively, driven by their participation in a study on AEs of AEDs. In conclusion, screening for adverse events of AEDs—independently of the screening tool used—is desired. However, that is insufficient to drive a significant improvement in AE burden and quality of life. Other measures are needed to address this critical problem in patients with medication-resistant epilepsy.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
